Homepage
Author:
ALTERITY THERAPEUTICS LIMITED
Posted Date:
May 8, 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
ALTERITY THERAPEUTICS LIMITED
May 8, 2026
Alterity Therapeutics to Deliver Presentations at Multiple Medical Conferences in May 2026
ALTERITY THERAPEUTICS LIMITED
May 7, 2026
Alterity Therapeutics Releases Appendix 4C – Q3 FY26 Quarterly Cash Flow Report & Corporate Update
ALTERITY THERAPEUTICS LIMITED
April 30, 2026
Alterity Therapeutics Receives Positive FDA Feedback Following Second Type C Meeting on ATH434 Phase 3 Program in Multiple System Atrophy
ALTERITY THERAPEUTICS LIMITED
April 27, 2026
Alterity Therapeutics Presents New Analysis of ATH434 Phase 2 Trial Data in Late Breaking Science Session of the American Academy of Neurology
ALTERITY THERAPEUTICS LIMITED
April 24, 2026
Alterity Therapeutics Appoints Highly Experienced Biotech Executive Ann Cunningham to its Board of Directors
ALTERITY THERAPEUTICS LIMITED
April 17, 2026
Alterity Therapeutics Announces Late-Breaker Oral Presentation at the American Academy of Neurology Annual Meeting
ALTERITY THERAPEUTICS LIMITED
April 16, 2026
Alterity Therapeutics to Host Virtual KOL Event to Share New Insights on ATH434 for the Treatment of Multiple System Atrophy
ALTERITY THERAPEUTICS LIMITED
April 15, 2026
Alterity Therapeutics Receives Positive FDA Feedback Following Type C Meeting on ATH434 Phase 3 Program
ALTERITY THERAPEUTICS LIMITED
March 30, 2026
Alterity Therapeutics to Participate in the Bell Potter Healthcare Horizons Summit
ALTERITY THERAPEUTICS LIMITED
March 9, 2026
1
2
Next
